Making Life-Saving Medical Treatments More Affordable

Recent years have brought significant innovation in potentially curative therapies for several diseases. By 2025, the FDA anticipates approving 10 to 20 cell and gene therapy products per year, many of which are intended to be one-time curative treatments.

But despite these efforts to accelerate the evaluation of drug safety and efficacy, uptake of many new therapies has been much slower than expected. Why the lag? Great thoughts in the latest Harvard Business Review from Precision Xtract team members James Baumgardner, Rebecca Kee, Scientific Advisor Dr. Bapu Jena and others.


Read the full article here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.